Article Versions Notes

Buchholz M, Majchrzak-Stiller B, Peters I, Hahn S, Skrzypczyk L, Beule L, Uhl W, Braumann C, Strotmann J, Höhn P. Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Cancers. 2024; 16(14):2612. https://doi.org/10.3390/cancers16142612

Buchholz, Marie, Britta Majchrzak-Stiller, Ilka Peters, Stephan Hahn, Lea Skrzypczyk, Lena Beule, Waldemar Uhl, Chris Braumann, Johanna Strotmann, and Philipp Höhn. 2024. "Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine" Cancers 16, no. 14: 2612. https://doi.org/10.3390/cancers16142612

Buchholz, M., Majchrzak-Stiller, B., Peters, I., Hahn, S., Skrzypczyk, L., Beule, L., Uhl, W., Braumann, C., Strotmann, J., & Höhn, P. (2024). Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Cancers, 16(14), 2612. https://doi.org/10.3390/cancers16142612